Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Shares Issued (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Shares Issued for 7 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued rose 383.24% year-over-year to $11.1 million, compared with a TTM value of $11.7 million through Dec 2025, up 1613.78%, and an annual FY2025 reading of $11.7 million, up 1613.78% over the prior year.
  • Shares Issued was $11.1 million for Q4 2025 at Arcturus Therapeutics Holdings, up from $116000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $11.1 million in Q4 2025 and bottomed at -$3.9 million in Q4 2024.
  • Average Shares Issued over 5 years is $954944.4, with a median of $265500.0 recorded in 2022.
  • The sharpest move saw Shares Issued plummeted 290.38% in 2024, then soared 954.55% in 2025.
  • Year by year, Shares Issued stood at -$157000.0 in 2021, then skyrocketed by 940.13% to $1.3 million in 2022, then surged by 56.1% to $2.1 million in 2023, then tumbled by 290.38% to -$3.9 million in 2024, then soared by 383.24% to $11.1 million in 2025.
  • Business Quant data shows Shares Issued for ARCT at $11.1 million in Q4 2025, $116000.0 in Q3 2025, and $274000.0 in Q2 2025.